The emergence and spread of artemisinin-partial resistant, malaria-causing Plasmodium falciparum provide the impetus for developing novel antimalarials. Pantothenamides are potent inhibitors of malaria parasite proliferation; however, their clinical use is hindered by pantetheinase-mediated degradation in human serum. Here, we report the synthesis and biological activity of a series of pantothenamide-mimics in which the thiazole ring replaces the labile amide bond with various orientations. Out of 23 novel compounds generated and tested in the presence of pantetheinase, several display sub-micromolar antiplasmodial activity in vitro. A selection of compounds was studied in more detail, and CoA biosynthesis and/or utilization pathways were confirmed to be the target. Toxicity to human cells was not observed. Kinetic studies identified the selected compounds as substrates of the HsPanK3 enzyme, but with much lower affinity compared to that of the natural substrate pantothenate. The most potent thiazole-bearing antiplasmodial compound was found to bind to PfPanK with a 120-fold higher affinity compared to HsPanK, highlighting excellent selectivity, not only against the key first enzyme in the CoA biosynthesis pathway but also at the whole-cell level. In conclusion, thiazole substitution of the labile amide bond represents a promising avenue for developing antimalarial pantothenamide-mimics.
Liu et al. (Wed,) studied this question.